News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
681,904 Results
Type
Article (41441)
Company Profile (200)
Press Release (640263)
Section
Business (204186)
Career Advice (2006)
Deals (35506)
Drug Delivery (76)
Drug Development (81666)
Employer Resources (167)
FDA (16030)
Job Trends (14912)
News (345460)
Policy (32640)
Tag
Academia (2615)
Africa (734)
Allergies (37)
Alliances (49425)
Alzheimer's disease (1117)
Antibody-drug conjugate (ADC) (49)
Approvals (15971)
Arizona (162)
Artificial intelligence (49)
Asia (37176)
Australia (6091)
Bankruptcy (351)
Best Places to Work (11282)
Biosimilars (55)
C2C Services and Suppliers (79209)
California (823)
Canada (642)
Cancer (185)
Career advice (1676)
CAR-T (33)
Cell therapy (66)
China (49)
Clinical research (63375)
Collaboration (58)
Colorado (33)
Compensation (30)
COVID-19 (2512)
Cystic fibrosis (71)
Diabetes (32)
Diagnostics (5925)
Diversity, equity & inclusion (44)
Drug pricing (49)
Earnings (82916)
Employer resources (141)
Europe (80118)
Events (107725)
FDA (16074)
Florida (106)
Funding (37)
Gene therapy (54)
GLP-1 (493)
Government (4316)
Healthcare (18684)
Hotbed/Location (483410)
Idaho (55)
Illinois (195)
Indiana (106)
Infectious disease (2525)
Inflammatory bowel disease (85)
Interviews (315)
IPO (16159)
Job creations (3669)
Job search strategy (1445)
Kansas (91)
Layoffs (379)
Legal (7879)
Liver cancer (51)
Lung cancer (38)
Maine (47)
Management (53)
Manufacturing (45)
Maryland (252)
Massachusetts (454)
Medical device (13012)
Medtech (13015)
Mergers & acquisitions (19046)
Metabolic disorders (161)
Neuroscience (1202)
New Jersey (62)
New York (84)
NextGen Class of 2024 (6520)
Non-profit (4513)
North Carolina (160)
Obesity (106)
Opinion (172)
Parkinson's disease (32)
Patents (33)
Peanut (33)
Pennsylvania (55)
People (55926)
Phase I (19707)
Phase II (27944)
Phase III (20824)
Policy (34)
Postmarket research (2586)
Preclinical (8471)
Rare diseases (92)
Real estate (5925)
Recruiting (63)
Regulatory (21167)
Reports (32)
Research institute (2367)
Resumes & cover letters (349)
South America (1109)
Startups (3636)
Texas (88)
United States (3020)
Vaccines (426)
Washington State (113)
Weight loss (102)
Date
Today (48)
Last 7 days (500)
Last 30 days (1930)
Last 365 days (38643)
2024 (21823)
2023 (40461)
2022 (51512)
2021 (56108)
2020 (54478)
2019 (46940)
2018 (35377)
2017 (32520)
2016 (31946)
2015 (38005)
2014 (31699)
2013 (26746)
2012 (28963)
2011 (29617)
2010 (27693)
681,904 Results for "promis neurosciences inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights
ProMIS Neurosciences Inc. announced financial results for the first quarter ended March 31, 2024 and provided a corporate update.
May 14, 2024
·
10 min read
ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio
ProMIS Neurosciences, Inc. announced that the European Patent Office, Japanese Patent Office and IP Australia, the Australian patent office, have recently allowed composition of matter and method of use patent applications related to ProMIS Neurosciences’ lead product candidate, PMN310, for the treatment of Alzheimer’s disease .
March 11, 2024
·
5 min read
ProMIS Neurosciences to Present in Upcoming Investor Conferences in April 2024
ProMIS Neurosciences Inc., a biotechnology company focused on the generation and development of therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, announced that company management will participate in three upcoming investor conferences.
April 4, 2024
·
1 min read
ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies
ProMIS Neurosciences Inc. announced the publication of a paper titled, “Relationship between therapeutic activity and preferential targeting of toxic soluble aggregates by amyloid-beta-directed antibodies,” in the online journal, bioRxiv.
April 30, 2024
·
6 min read
Genetown
ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference
ProMIS Neurosciences Inc. today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, will present at the 2024 BIO CEO & Investor Conference, taking place in-person in New York, NY on February 26-27, 2024.
February 22, 2024
·
1 min read
Business
ProMIS Neurosciences, Inc. Announces Leadership Transition
ProMIS Neurosciences Inc., a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease, amyotrophic lateral sclerosis and multiple system atrophy, announced a strategic leadership change.
January 3, 2024
·
6 min read
Drug Development
ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS
ProMIS Neurosciences Inc. today announced the publication of supportive preclinical data in the Journal of Biological Chemistry in an article titled, “Tryptophan residues in TDP-43 and SOD1 modulate the cross-seeding and toxicity of SOD1.”
April 9, 2024
·
5 min read
ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights
ProMIS Neurosciences Inc., a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease, amyotrophic lateral sclerosis and multiple system atrophy, announced financial results for the fiscal year ended December 31, 2023 and provided a corporate update.
April 1, 2024
·
11 min read
Press Releases
ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing
July 26, 2024
·
7 min read
ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine
ProMIS Neurosciences Inc. today announced the selection of a lead vaccine candidate, PMN400, against multiple synucleinopathies including Multiple System Atrophy (MSA), Parkinson’s disease and Lewy Body Dementia.
January 22, 2024
·
5 min read
1 of 68,191
Next